Updated on 10 September 2015
Cytori Therapeutics Inc. has appointed John D Harris as Vice President and General Manager of Cell Therapy, a newly created role to be based in Tokyo, Japan.
The role will focus on growth and development of the company's existing and future global cell therapy commercial operations. Harris' appointment will come into effect on October 1, 2015.
"Cytori has recruited a very accomplished executive to help us optimally position our therapeutic platform in the existing market, evaluate future global opportunities and to ensure we are prepared to transition to full commercial launch of our late-stage clinical programs," said Dr. Marc H Hedrick, President and CEO of Cytori. "John is uniquely qualified for this role for a number of reasons, including his demonstrated leadership capabilities, familiarity with the Japanese & Asia-Pacific markets, and his first-hand knowledge of global cell therapy trends and opportunities."
Harris joins Cytori from Becton Dickinson, where he serves as President of Becton Dickinson's Japanese operations, which include a production facility, over 550 employees, and approximately $315 million in revenues.
"I have followed the steady emergence of the cell therapy sector as well as its clinical and regulatory evolution for a number of years as both an executive at Becton Dickinson as well as a member of related industry groups here in Japan," said Harris.